论文部分内容阅读
目的:观察重组人血管内皮抑素联合顺铂胸腔热灌注治疗恶性胸腔积液的临床疗效和不良反应。方法:将90例合并恶性胸腔积液患者随机分为2组,每组45例。A组重组人血管内皮抑素+顺铂联合组:胸腔热灌注术循环时胸腔内注入顺铂40mg,术毕胸腔内注入重组人血管内皮抑制素30mg,2次/周,连续3周;B组顺铂组:胸腔热灌注术循环时胸腔内注入顺铂40mg,2次/周,连续3周。评价近期疗效、生活质量及不良反应。结果:A组RR 86.67%,B组53.33%(P<0.01)。A组生活质量改善者32例(71.11%),B组19例(42.22%)(P<0.01)。结论:重组人血管内皮抑素联合顺铂胸腔热灌注治疗恶性胸腔积液疗效显著,可明显改善患者的生活质量,不良反应小。
Objective: To observe the clinical efficacy and adverse reactions of recombinant human endostatin combined with cisplatin pleural hyperthermic perfusion in the treatment of malignant pleural effusion. Methods: Ninety patients with malignant pleural effusion were randomly divided into two groups, 45 cases in each group. A group of recombinant human endostatin + cisplatin combination group: Thoracic thermal perfusion during intrathoracic injection of cisplatin 40mg, intraoperative intrathoracic injection of recombinant human endostatin 30mg, 2 times / week for 3 weeks; B Group Cisplatin group: thoracic thermal perfusion during intrathoracic injection of cisplatin 40mg, 2 times / week for 3 weeks. Evaluation of the recent efficacy, quality of life and adverse reactions. Results: A group RR 86.67%, B group 53.33% (P <0.01). There were 32 cases (71.11%) in group A and 19 cases (42.22%) in group B (P <0.01). Conclusion: The therapeutic effect of recombinant human endostatin combined with Cisplatin in the treatment of malignant pleural effusion is remarkable, which can significantly improve the quality of life of patients with little adverse reactions.